|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.95 EUR | -0.10% |
|
+0.76% | +0.47% |
| 10/02 | FMC FRESENIUS MEDICAL CARE AG : UBS remains a Sell rating | ZD |
| 10/02 | Fresenius and Phlow partner to strengthen U.S. supply of essential medicine | RE |
| Capitalization | 11.32B 13.43B 10.32B 9.85B 18.29B 1,216B 19B 120B 47.65B 587B 50.36B 49.33B 2,053B | P/E ratio 2025 * |
13.1x | P/E ratio 2026 * | 11.2x |
|---|---|---|---|---|---|
| Enterprise value | 20.42B 24.23B 18.62B 17.78B 33B 2,195B 34.29B 217B 85.99B 1,060B 90.87B 89.01B 3,704B | EV / Sales 2025 * |
1.04x | EV / Sales 2026 * | 0.99x |
| Free-Float |
67.83% | Yield 2025 * |
3.61% | Yield 2026 * | 3.64% |
Last Transcript: Fresenius Medical Care AG
| 1 day | -0.10% | ||
| 1 week | +0.76% | ||
| Current month | +8.02% | ||
| 1 month | +10.77% | ||
| 3 months | +1.24% | ||
| 6 months | -3.76% | ||
| Current year | +0.47% |
| 1 week | 39.28 |  | 41.46 |
| 1 month | 35.67 | | 41.46 |
| Current year | 35.67 | | 41.46 |
| 1 year | 35.67 | | 54.02 |
| 3 years | 30.16 | | 54.02 |
| 5 years | 25.95 | | 71.14 |
| 10 years | 25.95 | | 93.82 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Giza
CEO | Chief Executive Officer | 58 | 06/12/2022 |
Martin Fischer
DFI | Director of Finance/CFO | 49 | 01/10/2023 |
| Chief Tech/Sci/R&D Officer | 56 | 01/01/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 59 | 12/05/2016 |
A. Sorensen
BRD | Director/Board Member | 64 | 20/05/2021 |
Michael Sen
CHM | Chairman | 57 | 14/07/2023 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.10% | +0.76% | -8.08% | +9.64% | 13.43B | |
| +0.95% | +7.69% | +70.86% | +108.57% | 121B | |
| +0.71% | +0.17% | +19.22% | -11.17% | 99.84B | |
| +0.56% | +1.81% | +35.96% | +79.01% | 33.86B | |
| +0.39% | +1.88% | -12.70% | +11.98% | 24.15B | |
| +1.63% | +1.96% | +14.66% | +13.85% | 23.43B | |
| +0.00% | +8.47% | +22.58% | +41.09% | 22.76B | |
| -0.50% | +14.76% | +73.36% | +274.49% | 20.31B | |
| +0.61% | +2.72% | +44.76% | +57.07% | 18B | |
| +0.32% | +7.44% | +29.34% | +58.51% | 14.67B | |
| Average | +0.46% | +4.68% | +29.00% | +64.30% | 39.12B | |
| Weighted average by Cap. | +0.66% | +4.45% | +37.99% | +60.87% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 19.57B 23.22B 17.85B 17.04B 31.63B 2,103B 32.86B 208B 82.4B 1,016B 87.09B 85.29B 3,550B | 19.95B 23.68B 18.2B 17.37B 32.25B 2,145B 33.51B 212B 84.03B 1,036B 88.8B 86.98B 3,620B |
| Net income | 902M 1.07B 823M 786M 1.46B 97B 1.52B 9.57B 3.8B 46.84B 4.02B 3.93B 164B | 1.02B 1.22B 934M 892M 1.66B 110B 1.72B 10.87B 4.31B 53.17B 4.56B 4.46B 186B |
| Net Debt | 9.1B 10.8B 8.3B 7.93B 14.71B 978B 15.29B 96.57B 38.33B 473B 40.51B 39.68B 1,651B | 8.48B 10.07B 7.74B 7.39B 13.72B 912B 14.25B 90.02B 35.73B 440B 37.76B 36.99B 1,539B |
Employees
109,916
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/02/26 | 40.95 € | -0.10% | 569,676 |
| 12/02/26 | 40.99 € | +2.14% | 1,162,465 |
| 11/02/26 | 40.13 € | -0.55% | 974,287 |
| 10/02/26 | 40.35 € | +1.41% | 1,176,505 |
| 09/02/26 | 39.79 € | -2.09% | 995,542 |
Sell
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
40.95EUR
Average target price
45.12EUR
Spread / Average Target
+10.19%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- FME Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition